Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AVBP
Upturn stock ratingUpturn stock rating

ArriVent BioPharma, Inc. Common Stock (AVBP)

Upturn stock ratingUpturn stock rating
$18.62
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: AVBP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $39.56

1 Year Target Price $39.56

Analysts Price Target For last 52 week
$39.56 Target price
52w Low $15.47
Current$18.62
52w High $36.37

Analysis of Past Performance

Type Stock
Historic Profit -10.3%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 755.39M USD
Price to earnings Ratio -
1Y Target Price 39.56
Price to earnings Ratio -
1Y Target Price 39.56
Volume (30-day avg) 7
Beta -
52 Weeks Range 15.47 - 36.37
Updated Date 08/15/2025
52 Weeks Range 15.47 - 36.37
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -4

Earnings Date

Report Date 2025-08-11
When -
Estimate -0.76
Actual -0.9

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -23.41%
Return on Equity (TTM) -50.06%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 519804737
Price to Sales(TTM) -
Enterprise Value 519804737
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 40568900
Shares Floating 24039128
Shares Outstanding 40568900
Shares Floating 24039128
Percent Insiders 8.24
Percent Institutions 72.9

ai summary icon Upturn AI SWOT

ArriVent BioPharma, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for patients with cancer. They often work on therapies originating in China, aiming to develop and commercialize them globally.

business area logo Core Business Areas

  • Drug Development and Commercialization: Focuses on in-licensing and developing oncology drugs, particularly those discovered and initially developed in China. Aims for global commercialization with focus on USA and China markets.

leadership logo Leadership and Structure

Bing Yao, Ph.D., is the current Chief Executive Officer. The company has a management team with experience in drug development and commercialization, and a board of directors with expertise in the pharmaceutical industry. Organizational structure follows typical biotech company structure with research, development, and commercial teams.

Top Products and Market Share

overview logo Key Offerings

  • Furmonertinib: Furmonertinib is ArriVent's lead product candidate, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed for the treatment of non-small cell lung cancer (NSCLC). The drug has shown potential in treating EGFR-mutated NSCLC. Competitors include Tagrisso (Osimertinib) from AstraZeneca and other EGFR TKIs.

Market Dynamics

industry overview logo Industry Overview

The oncology drug market is a large and rapidly growing market. Key trends include targeted therapies, immunotherapies, and personalized medicine. The market is highly competitive and driven by innovation.

Positioning

ArriVent BioPharma is positioned as a company focused on bringing innovative oncology therapies from China to the global market, targeting specific unmet needs in cancer treatment.

Total Addressable Market (TAM)

The global oncology market is projected to reach hundreds of billions of dollars. ArriVent aims to capture a portion of this TAM with its targeted therapies, initially focusing on EGFR-mutated NSCLC.

Upturn SWOT Analysis

Strengths

  • Experienced management team
  • Focus on innovative therapies
  • Strategic partnership model
  • Lead product candidate with promising clinical data

Weaknesses

  • Clinical stage company with no approved products
  • Reliance on partnerships
  • Relatively small company compared to established pharmaceutical companies
  • High risk of drug development failures

Opportunities

  • Growing oncology market
  • Unmet needs in cancer treatment
  • Potential for strategic partnerships
  • Expansion into new therapeutic areas

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Clinical trial failures
  • Intellectual property challenges

Competitors and Market Share

competitor logo Key Competitors

  • AZN
  • BMY
  • MRK
  • PFE

Competitive Landscape

ArriVent faces intense competition from larger, established pharmaceutical companies in the oncology market. ArriVent's advantage lies in its focus on innovative therapies in-licensed from China, but its smaller size and limited resources are disadvantages.

Growth Trajectory and Initiatives

Historical Growth: ArriVent BioPharma's historical growth is defined by its progress in drug development, partnerships, and funding rounds.

Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of its lead product candidate, Furmonertinib. Analyst estimates will be available after the company is more established.

Recent Initiatives: ArriVent's recent initiatives include advancing Furmonertinib through clinical trials and exploring new partnership opportunities.

Summary

ArriVent BioPharma is a clinical-stage company with a promising lead candidate. The company is strategically focused on bringing therapies from China to the global market. Successful clinical trials are the key. It faces high risk and competition from big pharma.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • ClinicalTrials.gov
  • Analyst Reports (estimates)

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ArriVent BioPharma, Inc. Common Stock

Exchange NASDAQ
Headquaters Newtown Square, PA, United States
IPO Launch date 2024-01-26
Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 52
Full time employees 52

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.